Home
#Global Trends
#Vietnam
#M&A
#Regulations
#Knowledge

Category: Uncategorized

Atossa Therapeutics Appoints Two Strategic Medical Directors for Oncology and Rare Diseases

21/03/2026 Published by vivi

On March 19, 2026, Seattle-based biopharmaceutical firm Atossa Therapeutics officially announced the addition of two key figures to its clinical... Read more

Tags: #Global Trends

Novartis agrees to $3B acquisition of mutant-selective breast cancer therapy

21/03/2026 Published by vivi

On March 20, 2026, Novartis announced an agreement with Synnovation Therapeutics to acquire Pikavation Therapeutics, the subsidiary holding the SNV4818... Read more

Category: Uncategorized

Tags: #Global Trends

Roche halts experimental SMA drug development following inconsistent trial results

21/03/2026 Published by vivi

On March 20, 2026, Swiss pharmaceutical giant Roche officially announced the discontinuation of emugrobart, an experimental antibody aimed at treating... Read more

Category: Uncategorized

Tags: #Global Trends

Earendil Labs hauls in $787M to advance AI-powered biologics

21/03/2026 Published by vivi

On March 20, 2026, Earendil Labs—a biotechnology startup with operations in both the U.S. and China—announced the successful closing of... Read more

Category: Uncategorized

Tags: #Global Trends

Novartis pays $2B to acquire precision breast cancer drug

21/03/2026 Published by vivi

On March 20, 2026, Swiss pharma giant Novartis announced the acquisition of Pikavation Therapeutics (a subsidiary of Synnovation Therapeutics) to... Read more

Category: Uncategorized

Tags: #M&A

Collegium pays $650M to acquire next-gen ADHD drug Azstarys

21/03/2026 Published by vivi

In a move to solidify its leadership in the attention-deficit/hyperactivity disorder (ADHD) market, Massachusetts-based Collegium Pharmaceutical has struck a deal... Read more

Category: Uncategorized

Tags: #M&A